Dr Malcolm Gillies[/caption]
PSA SA/NT Pharmacist of the Year Natasha Downing MPS[/caption]
PSA SA/NT ECP of the Year Raymond Truong MPS[/caption]
PSA SA/NT Intern of the YearChloe Hall MPS[/caption]
PSA SA/NT Lifetime Achievment Award recipient Peter Halstead FPS[/caption]
Pharmaceutical Society Gold Medal recipient Amelia Thompson[/caption]
Prof Danchin is a consultant paediatrician at the Royal Children’s Hospital and Clinician Scientist, University of Melbourne.
Overview of the categories 
Category B3
Patient considerations
Cannabis is the most popular recreational drug used in the world. The use of cannabis or cannabinoids is referred to as medicinal cannabis.
| Learning objectives
After reading this article, pharmacists should be able to:
Competencies (2016) addressed: 1.1.3, 1.3.1, 1.3.2, 3.1.2, 3.2.2, 3.2.3, 3.2.5, 3.3.1, 4.5.2. Competencies (2010) addressed: 1.1.1, 1.1.2, 1.2.1, 4.1.1, 4.1.3, 4.2.1, 4.2.2, 4.2.3, 4.3.3, 7.1.2, 7.2.2. |
Case scenario
A doctor from the medical centre down the road has called you to ask for some advice. He would like to know your opinion on the use of medicinal cannabis for the management of drug-resistant epilepsy. In particular, he is interested in how safe and effective it is, any contraindications, and when it would be appropriate to prescribe it for a patient.
Want to learn more? PSA members can access the full article and assessment questions here to earn up to 1.5 Group 2 CPD credits.
Not a PSA member? Find out why more than 18,000 pharmacists choose PSA to support, advance and create opportunities for the pharmacy career and the greater pharmacy profession. Click here to join today.
